rhinosinusitis%20-%20acute,%20bacterial
RHINOSINUSITIS - ACUTE, BACTERIAL
Acute bacterial rhinosinusitis is the mucosal inflammation of the nose and paransal sinuses caused by bacteria lasting >10 days for up to 4 weeks or symptoms worsening for 5-7 days within 10 days.
It is often preceded by a viral upper respiratory tract infection.
Signs and symptoms are nonspecific and typically difficult to differentiate from viral upper respiratory tract infection.
There is fever with nasal obstruction/congestion or anterior and/or posterior purulent drainage, with or without facial pressure/pain/fullness and reduction/loss of smell.
Streptococcus pneumoniae and unencapsulated strains of Haemophilus influenzae cause half of acute rhinosinusitis cases.

Principles of Therapy

General Antibiotic Therapy Principles

  • Empiric therapy should be started as soon as acute bacterial rhinosinusitis (ABRS) is diagnosed
    • Therapy should be based on cost, safety, likely pathogen, local resistance patterns & recent antibiotic use
  • Antibiotic therapy should be started in patients with the following presentations:
    • Severe ABRS: patient with >3 consecutive days fever (≥39°C) with purulent nasal discharge
    • Worsening ABRS: presence of nasal symptoms or cough during the day with acute-onset fever (≥38°C/100.4°F) worsening nasal discharge/daytime coughing after relief of symptoms
    • Persistent ABRS: >10 days symptoms (nasal discharge, cough) without signs of improvement
    • Severe, worsening or persistent ABRS with accompanying acute otitis media, pharyngitis, adenitis or pneumonia, or if suspected to have orbital or intracranial involvement
    • Uncomplicated severe, worsening or persistent ABRS without concomitant disease
  • Initial antibiotic prescribed should be the most narrow-spectrum agent that is active against the likely pathogens: S pneumoniae, H influenzae, M catarrhalis
    • Consider the local prevalence of resistance among each of the likely bacterial species
  • Initial empiric therapy coverage for S aureus or methicillin-resistant S aureus is not recommended
  • Factors that predispose patients to antibiotic-resistant bacteria need to be considered (eg antibiotic usage within the past month, hospitalization in the past 5 days, age <2 or >65 years, exposure to daycare, comorbid conditions, impaired immune response)

Goals of Antibiotic Therapy

  • Eradicate bacterial infection from the sinuses
  • Hasten resolution of symptoms
  • Prevent complications
  • Decrease the development of chronic disease

Pharmacotherapy

Mild Disease & No Antibiotics within the Last 4-6 weeks

  • In patients who have not responded to symptomatic therapy alone or those whose symptoms have worsened

Amoxicillin (Usual or High Dose)

  • Amoxicillin continues to be the agent of choice for ABRS due to its safety, efficacy, low cost and narrow microbiologic spectrum when still effective in the locality
  • In areas with high incidence of resistant S pneumoniae, high-dose Amoxicillin should be considered
  • Generally considered the most active of all oral beta-lactams against streptococci & only S pneumoniae that is highly resistant to Penicillin will not respond to conventional doses of Amoxicillin
    • Activity against beta-lactamase-negative strains of H influenzae is fair to good but it is ineffective against beta-lactamase-producing strains

Amoxicillin/Clavulanic Acid with or without High-Dose Amoxicillin

  • Recommended as initial empiric therapy for ABRS rather than Amoxicillin alone
  • Recommended in patients with moderate to severe disease who have failed high-dose Amoxicillin or if beta-lactamase-producing strains of H influenzae, M catarrhalis or oral anaerobes are suspected
  • Amoxicillin may be added to Amoxicillin/clavulanic acid to overcome drug resistance of S pneumoniae & should be considered in areas with high incidence of resistant S pneumoniae

Cephalosporins (2nd & 3rd Generation)

  • Eg Cefaclor, Cefdinir, Cefixime, Cefuroxime, Cefpodoxime, Ceftriaxone
  • Alternative agents that may be considered for patients with ABRS who have non-type 1 allergy to Penicillin
    • Because of variable resistance to S pneumoniae, it is not recommended for single-agent empiric therapy
    • Local resistance patterns & antimicrobial spectrum of the cephalosporins to S pneumoniae, H influenzae & M catarrhalis will need to be considered prior to choosing an agent
  • Cefaclor has poor overall efficacy against bacterial respiratory tract pathogens
  • Cefixime has potent activity against H influenzae
  • Cefpodoxime is the preferred agent for patients with treatment failure on high-dose Amoxicillin or Amoxicillin/clavulanic acid
    • Has similar activity with Cefuroxime & Cefdinir against S pneumoniae but greater efficacy against H influenzae
  • Cefuroxime has good efficacy against S pneumoniae but less active than Cefpodoxime against H influenzae
  • Intravenous/intramuscular Ceftriaxone (50 mg/kg single-dose) may be considered for patients intolerant to oral medications & highly unlikely to adhere to prescribed medications

Co-trimoxazole

  • Depending on the sensitivity pattern of local isolates, Co-trimoxazole may be considered an alternative for patients with type 1 allergy to Penicillin
    • Not advised for empiric therapy due to increased rates of resistance to both S pneumoniae & H influenzae

Doxycycline

  • Alternative agent to Amoxicillin/clavulanic acid in initial empiric therapy or to those who have type 1 allergy to Penicillin
  • Doxycycline has activity against Penicillin-susceptible pneumococci & M catarrhalis, but limited coverage for H influenzae
    • The probability of non-susceptibility to Doxycycline tends to rise in pneumococcal strains that have any level of Penicillin resistance

Macrolides

  • These agents may be considered alternatives in patients who have type 1 allergy to Penicillin
  • All macrolides have good activity against macrolide-susceptible pneumococci but are not recommended for empiric therapy because of increasing prevalence of macrolide-resistant S pneumoniae
  • Azithromycin & Clarithromycin are relatively weak against penicillin-resistant H influenzae & S pneumoniae
  • Telithromycin has been shown to have a targeted spectrum of activity against S pneumoniae, H influenzae, M catarrhalis

Moderate-Severe Disease or Antibiotics Received within the Last 4-6 weeks

  • Patients who failed 1st-line therapy may be considered with this group of patients

Amoxicillin/Clavulanic Acid with High Dose-Amoxicillin

  • Considered 1st-line agent by many authorities for patients who have failed Amoxicillin or in those with risk for resistant organisms
  • Therapy should be initiated using higher doses of Amoxicillin (add Amoxicillin therapy to Amoxicillin/clavulanic acid); this will increase the coverage of S pneumoniae

Ceftriaxone

  • 5-day therapy may be considered in those at risk for resistant organisms or in those who have failed 1st-line therapy

Respiratory Quinolones

  • Eg Levofloxacin, Moxifloxacin
  • Provides excellent coverage for all the likely pathogens, especially S pneumoniae & H influenzae
  • Because of the potential for increased resistance & toxicity, these agents should be reserved for adults with type 1 allergy to Penicillin & risk factors for resistant organisms, moderate disease, or in those who have failed recent antibiotic coverage

Combination Therapy

  • Eg Cefixime + high-dose Amoxicillin or Clindamycin or Rifampicin + high-dose Amoxicillin or Clindamycin
  • Combination therapy that has adequate Gram-positive & negative coverage may be considered in patients with risk of resistant organisms, moderate disease or have failed 1st-line therapy
  • At this time, there is no clinical evidence supporting the use or safety of combination therapy but it is recommended based on in vitro spectrum activity
  • Rifampicin + Clindamycin
    • Rifampicin should not be used as monotherapy or for longer than 10-14 days because resistance develops rapidly to this agent
  • Clindamycin/Linezolid + Cefixime
    • Recommended for patients with severe type 1 Penicillin hypersensitivity with moderate-severe sinusitis

Duration of Antibiotic Therapy

  • The appropriate duration of antibiotic therapy is not well defined
  • Most patients with ABRS that have been treated w/ the appropriate antibiotic agent will show clinical improvement within 48-72 hours
  • If ABRS is worse within 72 hours after initiating treatment:
    • If initially advised further observation, may start Amoxicillin with or without Clavulanate therapy
    • If initially prescribed with Amoxicillin, may increase dose & may add Clavulanate
    • If initially prescribed with high-dose Amoxicillin-Clavulanate, may shift to Clindamycin + Cefixime OR Linezolid + Cefixime OR Levofloxacin
  • No clinical improvement seen after 72 hours:
    • If initially advised further observation, may start antibiotic therapy
    • If initially prescribed with Amoxicillin, may initiate high-dose Amoxicillin/Clavulanate therapy
    • If initially prescribed with high-dose Amoxicillin-Clavulanate, may continue giving high dose Amoxicillin-Clavulanate OR may shift to Clindamycin + Cefixime OR Linezolid + Cefixime OR Levofloxacin
  • In patients without severe ABRS & comorbidities, may benefit from short-course treatment which leads to better compliance to treatment, fewer adverse effects, lower resistance rates and lower costs of medications
  • Short-course treatment with appropriate oral antibiotic treatment is given in 7 days
    • May be extended to 14 days if symptoms fail to resolve
  • The duration of antibiotic therapy in patients with moderate to severe ABRS is 7 to 14 days
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.

Pearl Toh, 22 May 2016
Asthma patients on salmeterol, a long-acting beta-agonist (LABA), plus fluticasone inhaled corticosteroid (ICS) combination therapy did not have a greater risk of serious asthma-related events compared with patients receiving fluticasone alone, according to the recent AUSTRI* study.